TCGA-CV-7104-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.089726027
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.670
- MYOGENESIS+0.570
- INTERFERON_GAMMA_RESPONSE+0.550
- INFLAMMATORY_RESPONSE+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- TNFA_SIGNALING_VIA_NFKB+0.470
- ANGIOGENESIS+0.430
- IL6_JAK_STAT3_SIGNALING+0.430
- PROTEIN_SECRETION+0.390
- COMPLEMENT+0.380
Top 10 suppressed
- E2F_TARGETS-0.460
- MYC_TARGETS_V1-0.450
- G2M_CHECKPOINT-0.380
- OXIDATIVE_PHOSPHORYLATION-0.330
- DNA_REPAIR-0.290
- MYC_TARGETS_V2-0.240
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.210
- PANCREAS_BETA_CELLS-0.160
- SPERMATOGENESIS-0.140
- UNFOLDED_PROTEIN_RESPONSE-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-5373-01A-01R-1436-07 | — | — | 0.920 |
| 2 | TCGA-CR-7386-01A-11R-2016-07 | — | — | 0.916 |
| 3 | TCGA-CN-4733-01A-02R-1873-07 | — | — | 0.909 |
| 4 | BS_1RXZ3BP7 | low-grade glioma | — | 0.903 |
| 5 | TCGA-64-5815-01A-01R-1628-07 | — | cohortA1 | 0.902 |
| 6 | TCGA-CN-5370-01A-01R-2016-07 | — | — | 0.901 |
| 7 | MDT-AP-3277 | Med | Medulloblastoma | 0.899 |
| 8 | BS_RRAEQZ97 | pilocytic astrocytoma | — | 0.898 |
| 9 | 2eaa09cd-8e3e-4de9-ab96-7a290d780a01 | — | — | 0.897 |
| 10 | BS_JWSR581E | low-grade glioma | — | 0.896 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.670 | Inavolisib | — uncovered |
| MYOGENESIS | 0.570 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.550 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.490 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.470 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.430 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.360 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.350 | Temsirolimus | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.340 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.310 | Inavolisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |